​

Cellectis (CLLS) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

CLLS Stock Rating

Cellectis stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (86.67%), 1 Hold (6.67%), 1 Sell (6.67%), and 0 Strong Sell (0.00%).

Buy
Total 15 1 1 13 0 Strong Sell Sell Hold Buy Strong Buy

CLLS Price Target Upside V Benchmarks

TypeNameUpside
StockCellectis-
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.37$1.37$1.37
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25222--6
May, 25221--5
Apr, 25221--5
Mar, 25221--5
Feb, 25231--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 12, 2024OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $-2 $1 $4 $7 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.71$-1.93$-2.17$-1.77-----
Avg Forecast$-2.19$-3.06$-2.30$-1.18$-0.53$-0.63$-0.50$-0.17$3.40
High Forecast$-1.07$-1.49$-1.11$-1.08$-0.24$-0.29$-0.23$-0.08$6.79
Low Forecast$-3.19$-4.47$-4.89$-1.28$-1.06$-1.27$-1.00$-0.34$1.53
Surprise %-21.92%-36.93%-5.65%50.00%-----

Revenue Forecast

$0 $70M $140M $210M $280M $350M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$73.95M$73.95M$19.17M$755.00K-----
Avg Forecast$62.04M$61.20M$32.85M$30.44M$52.01M$63.43M$77.99M$172.18M$129.67M
High Forecast$83.91M$82.78M$61.28M$30.96M$91.84M$112.02M$137.72M$304.07M$228.99M
Low Forecast$37.57M$37.06M$19.83M$29.93M$30.03M$36.63M$45.03M$99.42M$74.87M
Surprise %19.19%20.82%-41.64%-97.52%-----

Net Income Forecast

$-300M $-160M $-20M $120M $260M $400M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-72.57M$-86.28M$-98.69M$-101.06M-----
Avg Forecast$-124.80M$-174.64M$-131.14M$-67.53M$-30.29M$-36.16M$-28.69M$-9.69M$193.84M
High Forecast$-60.80M$-85.08M$-63.55M$-61.39M$-13.65M$-16.30M$-12.93M$-4.37M$386.86M
Low Forecast$-181.98M$-254.65M$-278.66M$-73.23M$-60.45M$-72.17M$-57.26M$-19.34M$87.36M
Surprise %-41.85%-50.59%-24.74%49.66%-----

CLLS Forecast FAQ

Is Cellectis stock a buy?

Cellectis stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Cellectis is a favorable investment for most analysts.

What is Cellectis's price target?

Cellectis's price target, set by 15 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.37.

How does Cellectis stock forecast compare to its benchmarks?

Cellectis's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Cellectis over the past three months?

  • June 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 40.00% Strong Buy, 40.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 40.00% Strong Buy, 40.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is Cellectis’s EPS forecast?

Cellectis's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.53, marking a -70.06% decrease from the reported $-1.77 in 2023. Estimates for the following years are $-0.63 in 2025, $-0.5 in 2026, $-0.17 in 2027, and $3.4 in 2028.

What is Cellectis’s revenue forecast?

Cellectis's average annual revenue forecast for its fiscal year ending in December 2024 is $52.01M, reflecting a 6788.25% increase from the reported $755K in 2023. The forecast for 2025 is $63.43M, followed by $77.99M for 2026, $172.18M for 2027, and $129.67M for 2028.

What is Cellectis’s net income forecast?

Cellectis's net income forecast for the fiscal year ending in December 2024 stands at $-30.287M, representing a -70.03% decrease from the reported $-101M in 2023. Projections indicate $-36.163M in 2025, $-28.69M in 2026, $-9.692M in 2027, and $193.84M in 2028.